Skip to content

Evaluation of the effect of oral Clonidine on reducing bleeding during hysterectomy

Evaluation of the effect of oral Clonidine on reducing bleeding during hysterectomy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211117053086N1
Enrollment
70
Registered
2022-01-18
Start date
2021-11-22
Completion date
Unknown
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hysterectomy.

Interventions

Intervention 1: The first group will be prescribed routine surgical preparations and clonidine tablets 0.2 (mg) 90 minutes before entering the operating room. This medicine will be provided by a Tolid

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patient informed consent No pregnancy and use of birth control pills Absence of systemic diseases and inherited or acquired coagulation disorders No history of ischemic heart disease No history of taking anticoagulants that affect bleeding No smoking and alcohol Known insensitivity to clonidine No history of repeated abdominal surgeries and the presence of abdominal adhesions

Exclusion criteria

Exclusion criteria: Raynaud's syndrome porphyria Renal dysfunction

Design outcomes

Primary

MeasureTime frame
Bleeding rate. Timepoint: Immediately after surgery. Method of measurement: Visual estimation scale: The number of normal gases impregnated in blood is multiplied by 10 ml and long gases by 50 ml and the result is added to the volume of suctioned blood. Since this volume is included in the volume of rinsing fluids in the surgical area; It also reduces the amount of fluid consumed and the result is equal to the amount of actual blood loss of the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBibi Fatemeh Alavi

Shahre-kord University of Medical Sciences

eslami@ualberta.ca+98 38 3222 8575

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026